Navigation Links
PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
Date:4/23/2013

SOUTH PLAINFIELD, N.J., April 23, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz , Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"It is an exciting opportunity to join PTC," stated Mr. Rothera. "Ataluren is in late-stage clinical development for patients with nonsense mutation Duchenne muscular dystrophy and cystic fibrosis. Both indications have no treatment options targeting the underlying cause of the disorder. I look forward to applying my experience in rare diseases to build a commercial function at PTC dedicated to serving patients around the world."

A veteran of the orphan drug arena, Mr. Rothera has spent 15 of his 23 years in the biopharmaceutical industry bringing new therapies to patients with rare diseases. Mr. Rothera served previously as Global President of Aegerion Pharmaceuticals Inc. where he was responsible for global commercial operations, manufacturing, and supply chain. Previously Mr. Rothera was Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies in Europe, the Middle East & Africa, where he was instrumental in leading growth through geographic expansion and the successful launches of three new therapies for rare diseases across 40 countries. Prior to Shire, Mr. Rothera held global strategic and operational marketing and sales roles with the French and UK operations of Glaxo Wellcome. Mr. Rothera's previous roles included Marketing Director, Europe at Amylin Pharmaceuticals, Commercial Director, Europe at PathoGenesis and Vice President Marketing & General Manager of the United Kingdom and Ireland at Chiron. Mr. Rothera received an MA in Natural Science from Cambridge University and an MBA from INSEAD.

"We are delighted to welcome Mark as a member of our senior management team," stated Stuart W. Peltz , Ph.D., CEO of PTC Therapeutics. "Mark's extensive experience in successfully launching several global orphan products makes him ideally suited to lead our anticipated commercial efforts. His track record as a champion for transformative therapies is only matched by his continued desire to impact the lives of those affected by rare and life-threatening disorders."


About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
2. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
3. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
4. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
5. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
6. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
7. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
10. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
11. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... presents its enhanced Pepper Flow promotional review platform at the Promotional Review ... increased insight-driven capabilities help marketers streamline the medical, legal, and regulatory review ...
Breaking Medicine News(10 mins):